@article{008796744d37493da5ef8b8928b73374,
title = "Translating research to usual care of children with sickle cell disease in Northern Nigeria: lessons learned from the SPRING Trial Team",
abstract = "Objectives: Evidence-based practice for stroke prevention in high-income countries involves screening for abnormal transcranial Doppler (TCD) velocity and initiating regular blood transfusions for at least 1 year, followed by treatment with hydroxyurea. This practice has not been transferred to low-resource settings like Nigeria, the country with the highest global population density of SCD. Following a multi-center randomized controlled trial among children with SCA in northern Nigeria, screening for stroke and initiation of hydroxyurea was established as standard of care at the clinical trial sites and other locations. We aim to describe the critical steps we took in translating research into practice for stroke prevention in SCA in Nigeria. Guided by the PRISM framework, we describe how we translated results from a randomized controlled trial for primary prevention of stroke in children with sickle cell anemia into usual care for children with SCA in Kaduna, Nigeria. Results: Findings from this study demonstrate the importance of organizational support and stakeholder involvement from the onset of a clinical trial. Having the dual objective of conducting an efficacy trial while simultaneously focusing on strategies for future implementation can significantly decrease the lag time between discovery and routine practice.",
keywords = "PRISM, Sickle cell disease, Stroke",
author = "Halima Bello-Manga and Lawal Haliru and Tabari, {Abdulkadir M.} and Bilkisu Farouk and Aisha Suleiman and Bahago, {Gloria Y.} and Sani, {Abdulrasheed M.} and Bauman, {Ana A.} and DeBaun, {Michael R.} and King, {Allison A.}",
note = "Funding Information: We are grateful to the leadership of Barau Dikko Teaching Hospital/Kaduna State University for the support given to us during the SPRING trial and beyond. We appreciate the Kaduna State Government through its Commissioner of Health for ensuring that hydroxyurea is provided free of charge for children with sickle cell disease identified to be at risk of developing stroke. Particularly, we appreciate Dr. Hamza Abubakar for being a ?champion? for this effort. We thank the members of the DeBaun laboratory at Vanderbilt-Meharry Center of Excellence in Sickle Cell Disease and Child Health and Education at Washington University in St. Louis School of Medicine for reviewing this manuscript. Funding Information: The SPRING trial is supported by the National Institutes of Health Grant #1R01NS094041. The sponsor did not have any role in the design and conduct of the study; the collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. HBM is supported by National Institutes of Health (Fogarty International Center and National Institutes of Neurological Disorders and Stroke) K43TW011583. AK was also supported by the National Institutes of Health 1K24 HL14830. Phillips Family donation provided funds for the transcranial Doppler ultrasonography machines. AAB is funded by UL1TR002345, 5U24HL136790, P50 CA-244431, 3D43TW011541-01S1, 1U24HL154426-01, 5U01HL133994-05, 3R01HD091218, 1 P50 MH122351-01A1. Publisher Copyright: {\textcopyright} 2021, The Author(s).",
year = "2022",
month = dec,
doi = "10.1186/s13104-021-05885-1",
language = "English",
volume = "15",
journal = "BMC Research Notes",
issn = "1756-0500",
number = "1",
}